RMD Open Submission Guide
A source-checked guide to testing rheumatology fit and assembling the evidence, reporting, and transparency package for RMD Open.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
Quick answer: Target RMD Open when the study answers a clear rheumatic or musculoskeletal disease question and transparent reporting makes the population, design, outcome, uncertainty, and practical or mechanistic consequence easy to audit. Open access does not lower the evidence burden.
Evidence basis: Current official sources linked below were rechecked on August 27, 2026. Publisher requirements and metrics are sourced; the manuscript-level decision artifact is Manusights editorial judgment, not an acceptance forecast.
Immediate decision | Evidence to inspect |
|---|---|
Proceed, repair, or reroute | Current official requirement, manuscript artifact, and explicit limitation |
Evidence basis: Current official sources linked below were rechecked on August 27, 2026. Publisher requirements and metrics are sourced; the manuscript-level decision artifact is Manusights editorial judgment, not an acceptance forecast.
Evidence basis: Current official sources linked below were rechecked on August 27, 2026. Publisher requirements and metrics are sourced; the manuscript-level decision artifact is Manusights editorial judgment, not an acceptance forecast.
Evidence basis: Current official sources linked below were rechecked on August 27, 2026. Publisher requirements and metrics are sourced; the manuscript-level decision artifact is Manusights editorial judgment, not an acceptance forecast.
Evidence basis: Current official sources linked below were rechecked on August 27, 2026. Publisher requirements and metrics are sourced; the manuscript-level decision artifact is Manusights editorial judgment, not an acceptance forecast.
Evidence basis: We reviewed the official RMD Open author information, journal site, and BMJ Author Hub on August 27, 2026. Publisher requirements are sourced; the readiness matrix and hold rules are Manusights editorial judgment.
Check the RMD evidence package.
From our manuscript review practice
Make population, disease decision, outcome, and evidence boundary visible together.
Use a rheumatology fit matrix
Manuscript job | What has to be visible | Hold signal |
|---|---|---|
Treatment or comparative effectiveness | Represented patients, comparator, outcome, harms, missingness, and follow-up | A surrogate or selected responder subgroup carries the conclusion |
Prognosis or prediction | Intended use, time origin, calibration, discrimination, and external test | Performance is shown only in the development cohort |
Imaging, biomarker, or classification | Reference standard, reliability, threshold, incremental value, and clinical route | Association is treated as diagnostic utility |
Mechanism | Disease-relevant model, discriminating perturbation, controls, and translation boundary | A pathway signal is presented as patient benefit |
The matrix is deliberately not a prestige ladder. The question is whether the manuscript helps RMD Open readers understand or act on a rheumatic-disease problem without hiding the evidence boundary.
Define the represented patient before the headline result
State the recruitment setting, diagnosis or classification criteria, disease stage, treatment era, comorbidity, exclusions, geography, and follow-up. If the conclusion applies only to a subset, say so in the title and abstract rather than leaving the limitation for the discussion.
For observational effectiveness work, distinguish treatment selection from treatment effect. For prediction work, show performance at a clinically meaningful horizon. For biomarker work, separate discrimination from added decision value.
Assemble the transparent package
- Confirm the current article type and limits on the official RMD Open author page.
- Attach the applicable reporting checklist through the EQUATOR Network.
- Reconcile registration, protocol, outcomes, analysis population, missingness, harms, and sensitivity analyses.
- Align patient and public involvement, ethics, consent, funding, conflicts, data, code, and contributor statements where applicable.
- Check the live official route immediately before upload.
Work the manuscript through one patient decision
Choose the single decision most changed by the evidence: diagnose, classify, treat, monitor, predict, implement, or explain. Then test whether the abstract, first figure, primary table, conclusion, and cover letter all support that decision with the same population and inference strength.
Worked example: biomarker association versus monitoring use
A marker may differ between active and inactive disease. That does not yet show that it can monitor an individual patient. A monitoring claim needs a defined use, timing, within-person behavior, reference comparison, threshold logic, uncertainty, and evidence that the result adds something to current assessment. Without that package, describe the marker as associated with disease activity and state what validation remains.
The final contradiction table
Surface | Verify | Repair before submission |
|---|---|---|
Title and abstract | Same disease population, endpoint, and inference | Practice-changing language from exploratory evidence |
Flow diagram | Every exclusion and analysis population | Denominators shift across figures and tables |
Primary result | Effect, uncertainty, harms, and time horizon | A p-value substitutes for magnitude and clinical meaning |
Supplement | Protocol, analysis, sensitivity, and reporting details | The key limitation appears only after the main conclusion |
Data and declarations | Access, privacy, ethics, conflicts, and contributions | Public-access wording conflicts with participant restrictions |
The failure patterns to catch before submission
In our analysis of the current official guidance and the manuscript decision implied by it, we found three checks that a generic publisher summary does not resolve. In our editorial analysis, the recurring failure pattern is a clinical-meaning jump: a biomarker, subgroup, or model result is described as if it already changes rheumatology care. Make the chain explicit from population and disease state through comparator, endpoint, effect size, uncertainty, missingness, sensitivity analysis, and the decision that remains justified after those limits are applied.
Inference jump. Test whether the conclusion moves from an observed result to mechanism, clinical use, or policy without the required comparison and validation.
Population jump. Compare the title, abstract, figure, methods, and conclusion for a change in the represented population, setting, model, or time horizon.
Package contradiction. Reconcile the main claim with the protocol, source files, supplement, data statement, ethics boundary, and cover letter before upload.
Observational rheumatology studies can audit disclosure against the STROBE explanation; trials should check CONSORT 2010; evidence syntheses should check PRISMA 2020. These references help test reporting completeness, while the live RMD Open author page controls article type and files.
This source-backed synthesis cannot predict acceptance or editorial priority. It identifies a manuscript-level decision that the publisher instructions do not make for an author.
Readiness check
Run the scan against the requirements while they're in front of you.
See score, top issues, and journal-fit signals before you submit.
Submit if
- A rheumatic-disease decision clearly owns the manuscript.
- The represented population and transfer boundary are explicit.
- The claim is proportional to design, validation, and uncertainty.
- Reporting and transparency artifacts agree across the package.
Think twice if
- The paper is being routed mainly because the journal is open access.
- A post hoc subgroup, surrogate, or selected clinic population carries a broad claim.
- The manuscript needs a more specialized basic-science, imaging, methods, or disease-specific readership.
- Important protocol or data limitations are disclosed only after the conversion point.
Run the final RMD Open readiness review.
Official sources accessed August 27, 2026.
Frequently asked questions
The manuscript should identify the rheumatic or musculoskeletal disease decision, represent the studied population honestly, and connect design, outcome, uncertainty, reporting, and clinical or mechanistic consequence.
Use the current RMD Open author page and BMJ Author Hub before upload because article types, policies, files, and fees can change.
Fit weakens when a broad rheumatology claim rests on a selected clinic population, surrogate outcome, post hoc subgroup, or mechanistic association without a clear boundary.
No. It provides a public-source readiness framework, not an acceptance forecast.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Your manuscript is never used to train any model.